Roche receives FDA approval for SJIA drug
According to Roche, the FDA’s decision was supported by the positive results from a randomized, double-blind, Phase III study which demonstrated that 85% of children with SJIA receiving
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.